Deramiocel Meets Phase 3 HOPE-3 Primary Endpoint, But Cardiac Data Miss
CAPR has more than doubled off its 52-week low of $2.96.
Summary
Capricor's deramiocel hit the primary endpoint in the Phase 3 HOPE-3 trial, improving upper-limb function in Duchenne muscular dystrophy patients. The cardiac side was weaker: overall heart function results were not statistically significant, extending the LVEF disappointment already flagged when the key secondary endpoint came in at p=0.09. That split matters because the FDA is weighing the BLA right now, with the PDUFA action date pushed to November 22, 2026 — four days from now. A third-party estimate puts approval odds at 62%, which is a coin-flip with a positive tilt, not a lock. The company has roughly $198.5 million in cash after a $42.7 million Q3 loss and a 10% workforce cut in September, so a complete response letter would leave it burning cash while it regroups. Watch November 22 for the FDA decision.
At the time of this announcement, CAPR was trading at $8.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $489M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.